Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03927534
Other study ID # 05/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2019
Est. completion date August 30, 2020

Study information

Verified date February 2021
Source Hospital Miguel Servet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mindfulness-Based Interventions have been applied in different fields to improve physical and psychological health. However, little is known about its applicability and effectiveness in Spanish adults with overweight and obesity. The aim of the present study protocol is to evaluate the feasibility and efficacy of an adapted MBI programme to reduce emotional eating in adults with overweight and obesity in primary care (PC) settings.


Description:

This study is a multi-centre, two-armed randomized controlled trial (RCT), with pre-treatment, post-treatment and 1-year follow-up measures, and a 1:1 allocation rate between groups. Patients from four mental health units in Zaragoza (Spain) will be randomly assigned to two different parallel conditions, with one psychological intervention group ('ME + TAU') and usual treatment ('TAU alone') managed by their general practitioner (GP), to test the superiority of 'ME + TAU' provision compared with 'TAU alone' provision. For ethical reasons, those patients allocated to 'TAU alone' will be offered the ME programme after finishing the trial at 1-year follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date August 30, 2020
Est. primary completion date August 31, 2019
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Age between 45-75 years - Have overweight or obesity condition based in BMI (Body Mass Index). Individuals with BMI of 25 or more. - Have two of these three risk: sedentary lifestyle, poor diet and binge episodes. - Ability to understand oral and written Spanish. - Willingness to participate in the study and signing informed consent. Exclusion Criteria: - Any diagnosis of a disease that may affect the central nervous system (brain condition, traumatic brain injury, dementia, etc). - Other psychiatric diagnoses or acute psychiatric illness (substance dependence or abuse, history of schizophrenia or other psychotic disorders, etc.), except for anxiety disorder or personality disorders. - Presence of delusional ideas or hallucinations whether consistent or not with mood. - Suicide risk.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindful Eating
The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.

Locations

Country Name City State
Spain Department of Psychiatry. Miguel Servet University Hospital Zaragoza

Sponsors (2)

Lead Sponsor Collaborator
Hospital Miguel Servet Dharamsala Institute of Mindfulness and Psychotherapy of Zaragoza

Country where clinical trial is conducted

Spain, 

References & Publications (11)

Fanning J, Osborn CY, Lagotte AE, Mayberry LS. Relationships between dispositional mindfulness, health behaviors, and hemoglobin A1c among adults with type 2 diabetes. J Behav Med. 2018 Dec;41(6):798-805. doi: 10.1007/s10865-018-9938-3. Epub 2018 May 25. — View Citation

Godsey J. The role of mindfulness based interventions in the treatment of obesity and eating disorders: an integrative review. Complement Ther Med. 2013 Aug;21(4):430-9. doi: 10.1016/j.ctim.2013.06.003. Epub 2013 Jul 9. Review. — View Citation

Hölzel BK, Lazar SW, Gard T, Schuman-Olivier Z, Vago DR, Ott U. How Does Mindfulness Meditation Work? Proposing Mechanisms of Action From a Conceptual and Neural Perspective. Perspect Psychol Sci. 2011 Nov;6(6):537-59. doi: 10.1177/1745691611419671. — View Citation

Kristeller JL, Hallett CB. An Exploratory Study of a Meditation-based Intervention for Binge Eating Disorder. J Health Psychol. 1999 May;4(3):357-63. doi: 10.1177/135910539900400305. — View Citation

Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare's search for effective obesity treatments: diets are not the answer. Am Psychol. 2007 Apr;62(3):220-33. Review. — View Citation

Mantzios M, Wilson JC. Mindfulness, Eating Behaviours, and Obesity: A Review and Reflection on Current Findings. Curr Obes Rep. 2015 Mar;4(1):141-6. doi: 10.1007/s13679-014-0131-x. Review. — View Citation

Mason AE, Epel ES, Kristeller J, Moran PJ, Dallman M, Lustig RH, Acree M, Bacchetti P, Laraia BA, Hecht FM, Daubenmier J. Effects of a mindfulness-based intervention on mindful eating, sweets consumption, and fasting glucose levels in obese adults: data from the SHINE randomized controlled trial. J Behav Med. 2016 Apr;39(2):201-13. doi: 10.1007/s10865-015-9692-8. Epub 2015 Nov 12. — View Citation

Medina WL, Wilson D, de Salvo V, Vannucchi B, de Souza ÉL, Lucena L, Sarto HM, Modrego-Alarcón M, Garcia-Campayo J, Demarzo M. Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview. Curr Diabetes Rev. 2017;13(2):141-147. doi: 10.2174/1573399812666160607074817. Review. — View Citation

Miller CK, Kristeller JL, Headings A, Nagaraja H, Miser WF. Comparative effectiveness of a mindful eating intervention to a diabetes self-management intervention among adults with type 2 diabetes: a pilot study. J Acad Nutr Diet. 2012 Nov;112(11):1835-42. doi: 10.1016/j.jand.2012.07.036. — View Citation

Rosenzweig S, Reibel DK, Greeson JM, Edman JS, Jasser SA, McMearty KD, Goldstein BJ. Mindfulness-based stress reduction is associated with improved glycemic control in type 2 diabetes mellitus: a pilot study. Altern Ther Health Med. 2007 Sep-Oct;13(5):36-8. — View Citation

Rössner S. Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord. 2002 Dec;26 Suppl 4:S2-4. Review. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary The Dutch Eating Behavior Questionnaire It was designed to measure eating styles that may attenuate or contribute to the development of overweight. It comprises three scales that measure emotional, external and restrained eating. The Spanish version of the DEBQ has 33 items, 13 of them referred to the emotional eating scale (e.g., "Desire to eat when irritated"), and 10 items referring to the external (e.g., "Eating when you feel lonely") and restrictive (e.g., "Difficult to resist delicious food") scales, respectively. The items can be rated on a five-point likert scale with 1 indicating "never" and 5 indicating "very often". Baseline in experimental and control groups.
Primary The Dutch Eating Behavior Questionnaire It was designed to measure eating styles that may attenuate or contribute to the development of overweight. It comprises three scales that measure emotional, external and restrained eating. The Spanish version of the DEBQ has 33 items, 13 of them referred to the emotional eating scale (e.g., "Desire to eat when irritated"), and 10 items referring to the external (e.g., "Eating when you feel lonely") and restrictive (e.g., "Difficult to resist delicious food") scales, respectively. The items can be rated on a five-point likert scale with 1 indicating "never" and 5 indicating "very often". Post-treatment 8 weeks from baseline in experimental and control groups
Primary The Dutch Eating Behavior Questionnaire It was designed to measure eating styles that may attenuate or contribute to the development of overweight. It comprises three scales that measure emotional, external and restrained eating. The Spanish version of the DEBQ has 33 items, 13 of them referred to the emotional eating scale (e.g., "Desire to eat when irritated"), and 10 items referring to the external (e.g., "Eating when you feel lonely") and restrictive (e.g., "Difficult to resist delicious food") scales, respectively. The items can be rated on a five-point likert scale with 1 indicating "never" and 5 indicating "very often". twelve-months follow-up in experimental and control groups
Secondary Sociodemographic data Gender, age, marital status, education, occupation, economical level Baseline in experimental and control groups
Secondary Five Facet Mindfulness Questionnaire The FFMQ-short form is a 24-item questionnaire that measures five aspects of mindfulness and there is a Spanish version based on it with appropriate psychometrics. The five facets the FFMQ measures are: observing (a = 81), describing (a = .87), acting with awareness (5 items, a = .83), non-judging to (5 items, a = .83) and non-reacting of (5 items, a = .75) inner experience. The participants indicate on a 5-point Likert scale the degree in which each item is generally true for them, ranging from 1 ("never or very rarely true") to 5 ("very often or always true"). Baseline in experimental and control groups
Secondary Five Facet Mindfulness Questionnaire The FFMQ-short form is a 24-item questionnaire that measures five aspects of mindfulness and there is a Spanish version based on it with appropriate psychometrics. The five facets the FFMQ measures are: observing (a = 81), describing (a = .87), acting with awareness (5 items, a = .83), non-judging to (5 items, a = .83) and non-reacting of (5 items, a = .75) inner experience. The participants indicate on a 5-point Likert scale the degree in which each item is generally true for them, ranging from 1 ("never or very rarely true") to 5 ("very often or always true"). Post-treatment 8 weeks from baseline in experimental and control groups
Secondary Five Facet Mindfulness Questionnaire The FFMQ-short form is a 24-item questionnaire that measures five aspects of mindfulness and there is a Spanish version based on it with appropriate psychometrics. The five facets the FFMQ measures are: observing (a = 81), describing (a = .87), acting with awareness (5 items, a = .83), non-judging to (5 items, a = .83) and non-reacting of (5 items, a = .75) inner experience. The participants indicate on a 5-point Likert scale the degree in which each item is generally true for them, ranging from 1 ("never or very rarely true") to 5 ("very often or always true"). twelve-months follow-up in experimental and control groups
Secondary Self-Compassion Scale It is the most used self-report instrument to measure self-compassion and it is divided into six subscales: Self-Kindness; Self-Judgment; Common Humanity; Isolation; Mindfulness; and Over-Identification. The items can be rated on a five-point Likert-type scale with 1 indicating "almost never" and 5 indicating "almost always". After reversing the negatively formulated items, a total score can be calculated, which may range from 24 to 120, with higher scores indicating greater self-compassion Baseline in experimental and control groups
Secondary Self-Compassion Scale It is the most used self-report instrument to measure self-compassion and it is divided into six subscales: Self-Kindness; Self-Judgment; Common Humanity; Isolation; Mindfulness; and Over-Identification. The items can be rated on a five-point Likert-type scale with 1 indicating "almost never" and 5 indicating "almost always". After reversing the negatively formulated items, a total score can be calculated, which may range from 24 to 120, with higher scores indicating greater self-compassion Post-treatment 8 weeks from baseline in experimental and control groups
Secondary Self-Compassion Scale It is the most used self-report instrument to measure self-compassion and it is divided into six subscales: Self-Kindness; Self-Judgment; Common Humanity; Isolation; Mindfulness; and Over-Identification. The items can be rated on a five-point Likert-type scale with 1 indicating "almost never" and 5 indicating "almost always". After reversing the negatively formulated items, a total score can be calculated, which may range from 24 to 120, with higher scores indicating greater self-compassion twelve-months follow-up in experimental and control groups
Secondary Mindful Eating Scale The MES scale has 28 items, including six factors: acceptance (a = .89), awareness (a = .82), non-reactivity (a = .77), act with awareness (a = .81), routine (a = .75) and unstructured eating (a = .60). Items can be rated on a 4-point Likert-type scale, with 1 indicating "never" and 4 indicating "very often". Baseline in experimental and control groups
Secondary Mindful Eating Scale The MES scale has 28 items, including six factors: acceptance (a = .89), awareness (a = .82), non-reactivity (a = .77), act with awareness (a = .81), routine (a = .75) and unstructured eating (a = .60). Items can be rated on a 4-point Likert-type scale, with 1 indicating "never" and 4 indicating "very often". Post-treatment 8 weeks from baseline in experimental and control groups
Secondary Mindful Eating Scale The MES scale has 28 items, including six factors: acceptance (a = .89), awareness (a = .82), non-reactivity (a = .77), act with awareness (a = .81), routine (a = .75) and unstructured eating (a = .60). Items can be rated on a 4-point Likert-type scale, with 1 indicating "never" and 4 indicating "very often". twelve-months follow-up in experimental and control groups
Secondary Bulimic Investigatory Test The BITE is very used to measure the presence and severity of bulimic symptoms in nonclinical samples. Normative values for BITE total and sub-scale scores in clinical and non-clinical samples are reported. The scale includes in the Symptoms subscale (30 yes-no items; range =0-30) and Severity subscale (6 dimensional items addressing specific bulimic behaviors; range=0-39). In addition to these standars scores, another measure was derived from the BITE-the reported frequency of bingeing Baseline in experimental and control groups
Secondary Bulimic Investigatory Test The BITE is very used to measure the presence and severity of bulimic symptoms in nonclinical samples. Normative values for BITE total and sub-scale scores in clinical and non-clinical samples are reported. The scale includes in the Symptoms subscale (30 yes-no items; range =0-30) and Severity subscale (6 dimensional items addressing specific bulimic behaviors; range=0-39). In addition to these standars scores, another measure was derived from the BITE-the reported frequency of bingeing Post-treatment 8 weeks from baseline in experimental and control groups
Secondary Bulimic Investigatory Test The BITE is very used to measure the presence and severity of bulimic symptoms in nonclinical samples. Normative values for BITE total and sub-scale scores in clinical and non-clinical samples are reported. The scale includes in the Symptoms subscale (30 yes-no items; range =0-30) and Severity subscale (6 dimensional items addressing specific bulimic behaviors; range=0-39). In addition to these standars scores, another measure was derived from the BITE-the reported frequency of bingeing twelve-months follow-up in experimental and control groups
Secondary Eating Attitude test (EAT-26) The EAT-26 had three subscales Dieting, Bulimia and Food Preocupation, and Oral Control. It is and abbreviated version of the original EAT-40, having an excellent correlation. In the EAT-26 each item is answered on a 6-point Lickert scale and if the scoring is 20 or higher the patient should look for professional advice. The Eat-26 had an elevated reliability Baseline in experimental and control groups
Secondary Eating Attitude test (EAT-26) The EAT-26 had three subscales Dieting, Bulimia and Food Preocupation, and Oral Control. It is and abbreviated version of the original EAT-40, having an excellent correlation. In the EAT-26 each item is answered on a 6-point Lickert scale and if the scoring is 20 or higher the patient should look for professional advice. The Eat-26 had an elevated reliability Post-treatment 8 weeks from baseline in experimental and control groups
Secondary Eating Attitude test (EAT-26) The EAT-26 had three subscales Dieting, Bulimia and Food Preocupation, and Oral Control. It is and abbreviated version of the original EAT-40, having an excellent correlation. In the EAT-26 each item is answered on a 6-point Lickert scale and if the scoring is 20 or higher the patient should look for professional advice. The Eat-26 had an elevated reliability twelve-months follow-up in experimental and control groups
Secondary Weight Weight measurement will be quantified in kilograms using a digital scale Baseline in experimental and control groups
Secondary Weight Weight measurement will be quantified in kilograms using a digital scale twelve-months follow-up in experimental and control groups
Secondary Abdominal perimeter Abdominal perimeter measurement will be quantified in centimetres using a measuring tape Baseline in experimental and control groupsw-up in experimental and control groups
Secondary Abdominal perimeter Abdominal perimeter measurement will be quantified in centimetres using a measuring tape twelve-months follow-up in experimental and control groups
Secondary Height Height measurement will be quantified in centimetres using a measuring tape Baseline in experimental and control groups
Secondary Height Height measurement will be quantified in centimetres using a measuring tape twelve-months follow-up in experimental and control groups
Secondary Cholesterol total Cholesterol total measurement will be quantified mg/dL using a blood test Baseline in experimental and control groups
Secondary Cholesterol total Cholesterol total measurement will be quantified mg/dL using a blood test twelve-months follow-up in experimental and control groups
Secondary LDL LDL measurement will be quantified mg/dL using a blood test Baseline in experimental and control groups
Secondary LDL LDL measurement will be quantified mg/dL using a blood test twelve-months follow-up in experimental and control groups
Secondary HDL HDL measurement will be quantified mg/dL using a blood test Baseline in experimental and control groups
Secondary HDL HDL measurement will be quantified mg/dL using a blood test twelve-months follow-up in experimental and control groups
Secondary Glucose Glucose measurement will be quantified mg/dL using a blood test Baseline in experimental and control groups
Secondary Glucose Glucose measurement will be quantified mg/dL using a blood test twelve-months follow-up in experimental and control groups
Secondary Alanine aminotransferase Alanine aminotransferase measurement will be quantified U/L using a blood test Baseline in experimental and control groups
Secondary Alanine aminotransferase Alanine aminotransferase measurement will be quantified U/L using a blood test twelve-months follow-up in experimental and control groups
Secondary Glycated haemoglobin Glycated haemoglobin measurement will be quantified in percentage (%) using a blood test Baseline in experimental and control groups
Secondary Glycated haemoglobin Glycated haemoglobin measurement will be quantified in percentage (%) using a blood test twelve-months follow-up in experimental and control groups
Secondary General Anxiety Disorder It is one of the most frequently used diagnostic self-report scales for screening, diagnosis and anxiety disorder severity assessment, defined as an excessive anxiety and worry (apprehensive expectation) related to a number of events or activities, associated to experiencing difficulties to control that worry. Items are rated on a 4-point Likert-type scale (between 0 = "not at all" and 3 = "nearly every day"). The GAD-7 inquires about events happening over the last two weeks, in order to know how often the patient has been bothered by them Baseline in experimental and control groups
Secondary General Anxiety Disorder It is one of the most frequently used diagnostic self-report scales for screening, diagnosis and anxiety disorder severity assessment, defined as an excessive anxiety and worry (apprehensive expectation) related to a number of events or activities, associated to experiencing difficulties to control that worry. Items are rated on a 4-point Likert-type scale (between 0 = "not at all" and 3 = "nearly every day"). The GAD-7 inquires about events happening over the last two weeks, in order to know how often the patient has been bothered by them twelve-months follow-up in experimental and control groups
Secondary Patient Health Questionnaire This scale is one of the most widely used questionnaires that assess the intensity of depression in pharmacological and psychological studies, it is useful to monitor changes experienced by patients over time. Through items like "Little interest or pleasure in doing things" and using a Liker-type scale from 0 ("not at all") to 3 ("nearly every day"), the PHQ-9 reflects the experience of participants during the last two weeks. Baseline in experimental and control groups
Secondary Patient Health Questionnaire This scale is one of the most widely used questionnaires that assess the intensity of depression in pharmacological and psychological studies, it is useful to monitor changes experienced by patients over time. Through items like "Little interest or pleasure in doing things" and using a Liker-type scale from 0 ("not at all") to 3 ("nearly every day"), the PHQ-9 reflects the experience of participants during the last two weeks. twelve-months follow-up in experimental and control groups
Secondary The diastolic blood pressure (DBP) and the systolic blood pressure (SBP) In order to evaluate the vital signs we will use a vascular screening system, in the version VaSera VS-1500. Baseline in experimental and control groups
Secondary The diastolic blood pressure (DBP) and the systolic blood pressure (SBP) In order to evaluate the vital signs we will use a vascular screening system, in the version VaSera VS-1500. twelve-months follow-up in experimental and control groups
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A